相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Toby M. Maher et al.
LANCET RESPIRATORY MEDICINE (2023)
Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease
Lisa Zhu et al.
ACR OPEN RHEUMATOLOGY (2021)
Upfront Combination Therapy With Rituximab and Mycophenolate Mofetil for Progressive Systemic Sclerosis
Doron Rimar et al.
JOURNAL OF RHEUMATOLOGY (2021)
Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Spectrum of Fibrotic Lung Diseases
Marlies Wijsenbeek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
K. R. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
Donald P. Tashkin et al.
LANCET RESPIRATORY MEDICINE (2016)
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
Aryeh Fischer et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
Suzana Jordan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Nonspecific Interstitial Pneumonia and Usual Interstitial Pneumonia: Is Differentiation Possible by High-Resolution Computed Tomography?
Takeshi Johkoh
SEMINARS IN ULTRASOUND CT AND MRI (2014)
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
Lesley Ann Saketkoo et al.
THORAX (2014)
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Idiopathic nonspecific interstitial pneumonia -: Report of an American Thoracic Society project
William D. Travis et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Rituximab-related viral infections in lymphoma patients
Sercan Aksoy et al.
LEUKEMIA & LYMPHOMA (2007)
Cyclophosphamide versus placebo in scleroderma lung disease
Donald P. Tashkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Characterization of lymphocyte populations in nonspecific interstitial pneumonia
KA Keogh et al.
RESPIRATORY RESEARCH (2005)
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
D Bouros et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Mycophenolate mofetil and its mechanisms of action
AC Allison et al.
IMMUNOPHARMACOLOGY (2000)
分享论文
